BioSpace News Archive

Clinical chatbot Gia offers new tools for OB/GYNs, oncologists, genetic counselors and other clinicians who order genetic testing

Rallybio LLC, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, announced the hiring of Michael Greco, JD to lead the Company’s legal function.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that the Canadian Patent Office has indicated its intent to grant the Company a patent for its invention titled “Methods and Compositions for Oral Administration of Proteins.”

Presentation highlighted the potential of the company’s lead candidate, the anti-SEMA4D antibody pepinemab, to regulate glial cell activation and neurodegeneration in Alzheimer’s and Huntington’s disease

Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that its Bioflux® units are designed for QT interval analysis, a section of the ECG, to identify serious risks like QT prolongation

Volpara Solutions announced it is collaborating with DetectED-X™, an online radiology training and research tool, to provide free access to learning modules on how radiologists can spot COVID‑19.

InGeneron announces publication of favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval on April 2 for its Remote Check solution. This approval is the first step in

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced that it has hired Robert Pietrusko, PharmD, as Chief Regulatory and Quality Officer.

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Simon Harford, Chief Financial Officer, will present via webcast at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, at 2:10 p.m. EDT.